Berkeley, CA, February 16, 2021 – Nexilico's collaboration with Microvi Biotech Inc. on developing precision biological processes was selected to receive a National Institutes of Health (NIH) Small Business Innovation Research (SBIR) grant for $1.12M. This collaborative project will further demonstrate the potential of advanced computational biology techniques to enhance development of disruptive microbiome-based technologies.
The project combines Microvi’s MicroNiche Engineering (MNE) Platform with Nexilico’s machine learning and microbiome modeling platforms. The outcome of this combination will have the potential to predict optimal microorganisms for a given water treatment application, drive the development of more targeted solutions, and increase the reliability and success of how those solutions can be applied.
Microvi is a transformative biology company based in the San Francisco Bay Area that delivers next-generation biotechnologies for the water, wastewater, bio-based chemicals, biofuels and biopharma industries. Microvi offers commercial technologies around the world to reduce waste, increase productivity and provide disruptive economics across the value chain. Learn more at www.microvi.com.
About the National Institutes of Health's Small Business Programs
NIH's SBIR and STTR programs are an integral source of capital for early stage U.S. small businesses to engage in federal research and development that has a strong potential for commercialization. These programs invest over 1 billion dollars into health and life science companies that are creating innovative technologies that align with NIH’s mission to improve health and save lives. A key objective is to translate promising technologies to the private sector and enable life-saving innovations to reach consumer markets. To learn more about NIH's Small Business programs, visit: https://sbir.nih.gov/
Disclaimer: Research reported in this press release was supported by National Institute of Environmental Health Sciences of the National Institutes of Health under award number R43GM130228. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Copyright © 2022 Nexilico, Inc. - All Rights Reserved.